Beacon Pointe Advisors LLC Purchases Shares of 40,773 Stryker Corporation $SYK

Beacon Pointe Advisors LLC acquired a new position in Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 40,773 shares of the medical technology company's stock, valued at approximately $12,838,000.

Several other institutional investors have also recently made changes to their positions in SYK. Sankala Group LLC purchased a new position in shares of Stryker in the fourth quarter valued at $26,000. Godfrey Financial Associates Inc. purchased a new stake in Stryker during the fourth quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter valued at $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker during the fourth quarter valued at $27,000. Finally, Gables Capital Management Inc. purchased a new position in shares of Stryker in the 2nd quarter worth $25,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Shares of SYK opened at $331.32 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a 50 day moving average price of $329.10 and a 200-day moving average price of $331.47. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The stock has a market capitalization of $127.08 billion, a PE ratio of 34.33, a PEG ratio of 2.05 and a beta of 0.76.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 earnings per share. Stryker's revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SYK shares. Raymond James Financial set a $370.00 price objective on Stryker in a research note on Friday, July 31st. Citigroup restated a "buy" rating on shares of Stryker in a report on Thursday, August 13th. Canaccord Genuity Group lowered their price target on Stryker from $435.00 to $400.00 and set a "buy" rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Wells Fargo & Company reduced their target price on shares of Stryker from $456.00 to $418.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $386.28.

Insiders Place Their Bets

In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company's stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of the firm's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source